FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...

Related Keywords

South Korea ,China ,Suzhou ,Jiangsu ,Princeton ,Massachusetts ,United States ,Shanghai ,Hangzhou ,Zhejiang ,Boston ,Guangzhou ,Guangdong ,Beijing ,Los Angeles ,Caroline Germa ,Product Development Center ,Transcenta Holding ,Prnewswire Transcenta Holding Limited ,Business Development Center ,Clinical Development Centers In Princeton ,Group Headquarters ,Global Medicine Development ,Translational Research Center ,Transcenta Immune Tolerance Breaking Technology ,Global Therapy ,Current Standard ,Holding Limited ,Drug Evaluation ,Transcenta Executive Vice President ,Chief Medical ,Cancer Statistics ,Mortality Worldwide ,Gastric Cancer Version ,Immune Tolerance Breaking Technology ,Orphan Drug Designation ,Manufacturing Facility ,Clinical Development Centers ,Suzhou Industrial ,Transcenta Holding Limited ,